Shanghai Henlius Biotech, Inc. (HKG:2696)
Hong Kong
· Delayed Price · Currency is HKD 67.55
+0.10 (0.15%)
Dec 5, 2025, 4:09 PM HKT
Shanghai Henlius Biotech Revenue
Shanghai Henlius Biotech had revenue of 2.82B CNY in the half year ending June 30, 2025, with 12.76% growth. This brings the company's revenue in the last twelve months to 5.80B, up 2.79% year-over-year. In the year 2024, Shanghai Henlius Biotech had annual revenue of 5.72B with 6.11% growth.
Revenue (ttm)
5.80B CNY
Revenue Growth
+2.79%
P/S Ratio
5.78
Revenue / Employee
1.65M CNY
Employees
3,515
Market Cap
36.71B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines AG | 38.69B |
| Hansoh Pharmaceutical Group Company | 14.45B |
| JD Health International | 71.34B |
| Innovent Biologics | 12.52B |
| WuXi Biologics | 21.98B |
| Sino Biopharmaceutical | 33.49B |
| Akeso | 2.75B |
| Sichuan Kelun-Biotech Biopharmaceutical | 1.64B |